Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Systolic Heart Failure: The DEFEAT-HF Study

Douglas P. Zipes, Petr Neuzil, Heinz Theres, David Caraway, Douglas L. Mann, Clas Mannheimer, Peter Van Buren, Cecilia Linde, Bengt Linderoth, Fred Kueffer, Scott A. Sarazin, Michael J L DeJongste

Research output: Contribution to journalArticle

52 Scopus citations

Abstract

Objectives: The primary objective of the study was a change in left ventricular end-systolic volume index (LVESVi) from baseline to 6 months of spinal cord stimulation (SCS) therapy in the treatment arm compared to the control arm as measured by echocardiography. Secondary objectives were changes in peak oxygen uptake and N-terminal pro-B-type natriuretic peptide (NT-proBNP) between the treatment arm and control arm from baseline through 6 months. Background: Abnormal neurohormonal activation is often responsible for progression of heart failure (HF). Treatment has often included drug therapy to modulate the neurohormonal axis. The purpose of the DEFEAT-HF (Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure) clinical study was to evaluate whether direct modulation of the nervous system through SCS improved HF metrics, including heart size, biomarkers, functional capacity, and symptoms. Methods: The DEFEAT-HF study was a prospective, multicenter randomized (3:2), parallel, single-blind, controlled study to investigate whether SCS was a feasible therapy for the treatment of systolic HF for patients with New York Heart Association functional class III HF, left ventricular ejection fraction (LVEF) ≤35%, QRS duration

Original languageEnglish (US)
Pages (from-to)129-136
Number of pages8
JournalJACC: Heart Failure
Volume4
Issue number2
DOIs
StatePublished - Feb 1 2016

Keywords

  • Clinical trial results
  • Heart failure
  • Randomized
  • Spinal cord stimulation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Systolic Heart Failure: The DEFEAT-HF Study'. Together they form a unique fingerprint.

  • Cite this

    Zipes, D. P., Neuzil, P., Theres, H., Caraway, D., Mann, D. L., Mannheimer, C., Van Buren, P., Linde, C., Linderoth, B., Kueffer, F., Sarazin, S. A., & DeJongste, M. J. L. (2016). Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Systolic Heart Failure: The DEFEAT-HF Study. JACC: Heart Failure, 4(2), 129-136. https://doi.org/10.1016/j.jchf.2015.10.006